Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 20.03.17 in Vol 6, No 3 (2017): March

This paper is in the following e-collection/theme issue:

Works citing "Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.7289):

(note that this is only a small subset of citations)

  1. Sharman JP, Wheler JJ, Einhorn L, Dowlati A, Shapiro GI, Hilton J, Burke JM, Siddiqi T, Whiting N, Jalal SI. A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. Investigational New Drugs 2019;37(4):738
    CrossRef
  2. Nassif S, El-Zaatari ZM, Attieh M, Hijazi M, Fakhreddin N, Aridi T, Boulos F. Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics. Medicine 2019;98(32):e16702
    CrossRef
  3. Stillman RC. Clinical Decision Support Tools Improving Cancer Care. Seminars in Oncology Nursing 2018;34(2):158
    CrossRef
  4. Dalton WS, Sullivan D, Ecsedy J, Caligiuri MA. Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. Clinical Pharmacology & Therapeutics 2018;104(1):23
    CrossRef